Crism Therapeutics annual free cash flow
2023
2024
2025
Crism Therapeutics reported −£2.0M in free cash flow for fiscal 2025, a decrease of £1.0M from the previous fiscal year, with a free cash flow margin of −864.94%.
View full Crism Therapeutics company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −£2.0M | −£1.0M | — | −864.94% |
| 2024 | 2024-12-31 | −£961,000 | −£851,000 | — | −3844.00% |
| 2023 | 2023-12-31 | −£110,000 | — | — | −244.44% |
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Crism Therapeutics source filings ↗